Shimada, E.; Endo, M.; Matsumoto, Y.; Tsuchihashi, K.; Ito, M.; Kusaba, H.; Nabeshima, A.; Nawata, T.; Maekawa, A.; Matsunobu, T.;
et al. Does the Use of Peripheral Immune-Related Markers Indicate Whether to Administer Pazopanib, Trabectedin, or Eribulin to Advanced Soft Tissue Sarcoma Patients? J. Clin. Med. 2021, 10, 4972.
https://doi.org/10.3390/jcm10214972
AMA Style
Shimada E, Endo M, Matsumoto Y, Tsuchihashi K, Ito M, Kusaba H, Nabeshima A, Nawata T, Maekawa A, Matsunobu T,
et al. Does the Use of Peripheral Immune-Related Markers Indicate Whether to Administer Pazopanib, Trabectedin, or Eribulin to Advanced Soft Tissue Sarcoma Patients? Journal of Clinical Medicine. 2021; 10(21):4972.
https://doi.org/10.3390/jcm10214972
Chicago/Turabian Style
Shimada, Eijiro, Makoto Endo, Yoshihiro Matsumoto, Kenji Tsuchihashi, Mamoru Ito, Hitoshi Kusaba, Akira Nabeshima, Tomoya Nawata, Akira Maekawa, Tomoya Matsunobu,
and et al. 2021. "Does the Use of Peripheral Immune-Related Markers Indicate Whether to Administer Pazopanib, Trabectedin, or Eribulin to Advanced Soft Tissue Sarcoma Patients?" Journal of Clinical Medicine 10, no. 21: 4972.
https://doi.org/10.3390/jcm10214972
APA Style
Shimada, E., Endo, M., Matsumoto, Y., Tsuchihashi, K., Ito, M., Kusaba, H., Nabeshima, A., Nawata, T., Maekawa, A., Matsunobu, T., Setsu, N., Fujiwara, T., Iida, K., Nakagawa, M., Hirose, T., Kanahori, M., Oyama, R., Isobe, T., Ariyama, H.,
... Nakashima, Y.
(2021). Does the Use of Peripheral Immune-Related Markers Indicate Whether to Administer Pazopanib, Trabectedin, or Eribulin to Advanced Soft Tissue Sarcoma Patients? Journal of Clinical Medicine, 10(21), 4972.
https://doi.org/10.3390/jcm10214972
